Abstract
A series of eight 1-substituted imidazoles was investigated as model substrates for glucuronidation at an aromatic tertiary amine of polyaza heterocyclic ring systems. The human UDP-glucuronosyltransferases (UGTs) involved and substrate specificities were investigated. Nine expressed enzymes (UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A7, UGT1A9, UGT1A10, UGT2B7, and UGT2B15) were examined, but only UGT1A4 catalyzed the formation of a quaternary ammonium-linked glucuronide metabolite for six of the substrates. UGT1A3 also catalyzed the glucuronidation of the previously investigated 1-phenylimidazole but none of the newly investigated compounds. No glucuronidation was observed with 1-(4-nitrophenyl)imidazole, the compound with the 4-phenyl substituent with the largest electron withdrawing effect. The incubation conditions for the determination of the kinetic constants for UGT1A4 catalysis of six substrates were optimized and included incubation at pH 7.4 with alamethicin at 10 μg/mg of protein. Latency disrupting agents, including alamethicin and sonication, enhanced glucuronidation 1.25-fold at most. There were 17.5- and 2.2-fold variations in the apparent Km (range, 0.18–3.15 mM) and Vmax values (range, 0.16–0.35 nmol/min/mg of protein). Linear correlation analyses between UGT1A4 kinetics and substrate physicochemical parameters showed significant correlation between Vmax and both the partition coefficient (log P, n-octanol/water) and pKa and betweenKm and pKa, thereby indicating that the lipophilicity and the ease of availability of the tertiary amine lone pair of electrons of the substrate are important with respect to enzyme catalysis.
The glucuronidation of tertiary aliphatic or aromatic amines leading to the formation of a polar quaternary ammonium-linked glucuronide metabolite (N+ -glucuronide) (Tukey and Strassburg, 2000) plays a significant role in the metabolism of various xenobiotics. Examples of these substrates include various H1 antihistamine and tricyclic antidepressant drugs (Hawes, 1998; Dalgaard and Larsen, 1999; Mey et al., 1999) in the case of aliphatic amines and anastrozole (McCann et al., 1997), lamotrigine (Sinz and Remmel, 1991), nicotine (Caldwell et al., 1992), and tioconazole (MacRae et al., 1990) in the case of aromatic amines. Basic knowledge is lacking regarding this metabolic route, especially in the case of glucuronidation at an aromatic tertiary amine. These deficiencies include the identification of the UDP-glucuronosyltransferase (UGT3) enzymes involved in catalysis at an aromatic tertiary amine and substrate specificities.
In humans, members of the UGT1A and UGT2B subfamilies are considered to be mainly involved in the catalysis of the glucuronidation of xenobiotics. However, primarily UGT1A enzymes are known to catalyzeN-glucuronidation, where metabolite formation is far more selective for tertiary than primary or secondary amine substrates. In fact, only UGT1A3 and UGT1A4 have been demonstrated to catalyze the glucuronidation of tertiary amine substrates (Green et al., 1995, 1998;Green and Tephly, 1996, 1998; Breyer-Pfaff et al., 2000). However, whereas such has been demonstrated for many substrates with respect to aliphatic tertiary amines, only in the case of UGT1A4 catalysis of lamotrigine glucuronidation had aromatic tertiary amines been investigated (Green et al., 1995). Previous structure-metabolism relationship studies of glucuronidation that relate physicochemical features to metabolic kinetics are limited and involveO-glucuronidation.
To investigate both the UGT enzyme(s) involved in the catalysis of glucuronidation at an aromatic tertiary amine and the structure-metabolism relationships thereof, a series of 1-substituted imidazoles ( 1a –1h ) (Fig.1), which appropriately differ in their electronic (ςpara, ς value for the substituent in the para position of the phenyl ring), lipophilic (log P; or πpara, π value for the substituent in the para position of the phenyl ring), and pKa properties, was selected for study (Kubinyi, 1995). The reasons why this series was selected for study include the following.
1) Many drugs contain five-membered heterocyclic ring systems as part of their structure, and examples are known where a majorN+ -glucuronide metabolite is formed in humans (MacRae et al., 1990; Rush et al., 1990, 1992; McCann et al., 1997). 1-Substituted imidazoles serve as a model for such ring systems, having only one aliphatic-like tertiary amine and one aromatic-type tertiary amine at the 1 and 3 positions, respectively. Also, there is generally greater commercial availability or synthetic accessibility of imidazoles than polyaza ring systems such, as triazoles or tetrazoles.
2) 1-Substituted imidazoles, including 1-phenyl substituted imidazoles, are appropriate substrates to investigate correlations between physicochemical properties (electronic, lipophilic, and pKa) of the substrates and their kinetic parameters (Km,Vmax, andVmax/Km).
3) A previous study from this laboratory of the prototype molecule 1-phenylimidazole ( 1a ) demonstrated the definitive identification of theN+-glucuronide metabolite in human liver microsomes and that only human UGT1A3 and UGT1A4 of the nine UGT enzymes examined catalyzed N-glucuronidation (Vashishtha et al., 2000).
The specific objectives of this study were to identify the UGTs enzyme(s) involved in the catalysis of the glucuronidation of the series 1 compounds and to determine, for the identified UGT(s), the kinetic parameters for each 1-substituted imidazole and the relative importance of various physicochemical parameters in theN-glucuronidation of the selected series 1 compounds.
Materials and Methods
Chemicals.
1-Phenylethylimidazole ( 1c ) was synthesized by a literature procedure (Salerno et al., 1999). All other substrates [1-phenylimidazole ( 1a ), 1-(4-methoxyphenyl)imidazole ( 1d ), 1-(4-chlorophenyl)imidazole ( 1e ), 1-(4-bromophenyl)imidazole ( 1f ), 1-(4-trifluoromethylphenyl)imidazole ( 1g ), 1-(4-nitrophenyl)imidazole ( 1h ) (Transworld Chemicals, Rockville, MD), and 1-benzylimidazole ( 1b ) (Lancaster, Windham, NH)] were obtained from commercial sources. The metabolite 1-phenylimidazoleN+-glucuronide was synthesized by a literature procedure (Vashishtha et al., 2000). Perchloric acid (BDH Chemicals, Toronto, Ontario, Canada), methimazole, Brij-58, CHAPS, Lubrol PX, Triton X-100, Tris base, alamethicin, ethyl 2-pyridylacetate, UDP-glucuronic acid (UDPGA) (ammonium salt), magnesium chloride, and d-saccharic acid 1,4-lactone (Sigma, St. Louis, MO) were also obtained commercially. Emulgen 911 was a gift from the Kao Corporation (Tokyo, Japan). Although all the chemicals were of reagent grade, the organic solvents (EM Science, Gibbstown, NJ) were of HPLC grade. Double-distilled water, deionized and purified by a Milli-Q water system (18 ± 0.05 ohm/cm) (Millipore Corporation, Bedford, MA), was used. HPLC mobile phase solvents were filtered through Millipore 0.45-μm filters before use.
HPLC Analysis.
Separation and quantification of the glucuronide metabolites produced in recombinant cell microsomes were achieved by gradient reversed-phase HPLC on a chromatographic system consisting of two HPLC pumps (Waters model 501, Milford, MA), an automated gradient controller (Waters model 680), and a variable wavelength absorbance detector (Waters model 486). Samples were injected via an autosampler SCL-10A (Shimadzu Corporation, Kyoto, Japan), and the separation was achieved on an Ultracarb C18 analytical column (ODS 30; 4.6 × 250 mm; Phenomenex, Torrance, CA) packed with 5-μm diameter particles. The analytical column, maintained at ambient temperature, was protected using security guard C18 cartridges (4 × 3.0 mm; Phenomenex). Data acquisition and integration were performed using a Waters Maxima 820 chromatography workstation. The total flow rate of the mobile phase was 1.0 ml/min. The chromatographic conditions regarding the solvent compositions (solvent A/solvent B) of the mobile phase consisting of solvent A (10 mM perchloric acid, pH 2.5) and solvent B (acetonitrile), the wavelength of maximum absorption, and the external standards (in parenthesis) for the quantitative analysis of the glucuronide of each substrate were as follows: 1a , 88:12 to 99:1 for 9 min, 88:12 for 10 to 15 min, 236 nm (2-ethylpyridyl acetate); 1b , 88:12 for 5 min, 84:16 for 6 to 20 min, 220 nm (methimazole); 1c , 88:12 for 10 min, 80:20 for 11 to 28 min, 220 nm (methimazole); 1d , 88:12 for 5 min, 85:15 for 6 to 15 min, 240 nm (methimazole); 1e , 90:10 for 10 min, 80:20 for 11 to 25 min, 240 nm (methimazole); 1f , 88:12 for 10 min, 84:16 for 11 to 25 min, 240 nm (methimazole); 1g , 78:22 for 5 min, 75: 25 for 6 to 25 min, 243 nm ( 1e ).
The respective retention times of the substrateN+-glucuronide and external standard were as follows: 1a , 18.39, 6.43, 12.11 min; 1b , 18.67, 9.30, 4.86 min; 1c , 25.74, 15.28, 4.74 min; 1d , 22.52, 12.01, 5.28 min; 1e , 23.53, 16.07, 4.59 min; 1f , 24.51, 19.31, 4.88 min; 1g , 20.16, 10.20, 12.78 min.
The amount of N+-glucuronide formed (nanomoles per minute per milligram of protein) was calculated based on the ratio of the peak areas of theN+-glucuronide and an external standard. A UV absorption study of 1a and its metabolite 1-phenylimidazole N+ -glucuronide revealed that their extinction coefficients are very similar. Therefore, except for 1a (where a pure synthetic sample of metabolite was used), each metabolite was quantified using standard curves made from standard solutions of the substrates.
Identification of Human UGT Enzyme(s) Catalyzing theN-Glucuronidation of 1-Substituted Imidazoles.
Microsomal recombinant human UGT enzymes, expressed in human lymphoblastoid cells [UGT1A1, UGT1A4, UGT1A6, UGT1A9, UGT2B15, and control microsomes (without vector)] were purchased from GENTEST (Woburn, MA). Microsomes from Spodoptera frugiperda-9 insect cells infected with a baculovirus containing cDNA for human UGT1A3, UGT1A7, UGT1A10, and UGT2B7, and S. frugiperda-9-WT control baculosomes were purchased from Pan Vera (Madison, WI). The suppliers gave the protein content and glucuronidation activity data of a reference substrate of each expressed enzyme. Also, in the case of UGT1A3, 4-nitrophenol served as an in-house positive control, where under the following general UGT-screening conditions, the glucuronidation activity was determined to be 92.7 ± 2.4 pmol/min/mg of protein. The control products were used as negative controls for their respective UGT preparations.
For general UGT screening, the substrate (1.25 mM 1b –1h in 2.5 μl of methanol) was incubated with a mixture (200 μl) consisting of MgCl2 (10 mM), saccharic acid lactone (3 mM), alamethicin (12.5 μg/mg of protein), UDPGA (5 mM), cellular protein (0.2 mg), and Tris buffer (50 mM, pH 7.4) for 60 min at 37°C. After terminating the reaction by keeping the tube at 4°C and adding 190 μl of perchloric acid (1%), the external standard (10 μl) was added, and the microsomal mixture was centrifuged at 9000g for 15 min. The supernatant (100 μl) was then analyzed using HPLC-UV, as described above.
Enzyme Kinetic Studies of N-Glucuronidation of 1-Substituted Imidazoles using Human UGT1A4 Expressed in Baculovirus-Infected Insect Cells.
Supersomes (GENTEST) prepared from baculovirus-infected insect cells (BTI-TN-5B1-4) expressing human UGT1A4 cDNA were used to determine the kinetic parameters of the substrates. For this preparation, the manufacturer determined that the rate of formation is 1.14 nmol/min/mg of protein for glucuronidation at an aliphatic tertiary amine group of trifluoperazine. Using 1-phenylimidazole as a prototypic substrate, the incubation conditions were optimized with respect to pH, latency-disrupting agents, time of incubation, and the protein concentration required to give the linear rate of formation of the glucuronide. The effect of pH on the rate of glucuronidation was examined in the range of 6.0 to 9.0 (6.0, 6.5, 7.0, 7.4, 8.0, 8.5, and 9.0). Various latency-disrupting agents, a pore-forming peptide (alamethicin) and five detergents (Brij-58, CHAPS, Emulgen 911, Lubrol PX, and Triton X-100) were examined initially at a concentration of 100 μg/mg of protein. Subsequently, alamethicin (0, 2, 5, 10, 20, 100, and 400 μg/mg of protein) and Emulgen 911 (20, 100, and 400 μg/mg of protein) were examined over a wide concentration range. Also, the effectiveness of sonication was investigated that involved one, two, or three 4- to 5-s bursts with at least 1 min on ice between bursts. For all substrates, the time of incubation and the protein concentration were varied from 15 to 75 min (15, 30, 45, 60, and 75 min), and 125 to 1000 μg/ml (125, 250, 500, 750, and 1000 μg/ml), respectively. Each experiment was carried out in triplicate.
The general procedure for the determination of the kinetic parameters of the substrates 1a to 1g is as follows: the microsomal mixture (200 μl), consisting of MgCl2 (10 mM), saccharic acid lactone (3 mM), alamethicin (10 μg/mg of protein), UDPGA (5 mM), UGT1A4 protein (0.075–0.1 mg depending upon the substrate), Tris buffer (50 mM, pH 7.4), and the substrate (variable concentrations) in 2.5 μl methanol, was incubated for the appropriate time interval (45–60 min depending upon the substrate) at 37°C. The reaction was then processed as described above. All analyses were performed three times, each in duplicate. The kinetic parameters were determined from the data obtained by the incubation of 8 to 10 different concentrations of the various substrates.
Calculations.
Kinetic parameters were calculated according to the Michaelis-Menten equation for one or two enzymes by nonlinear least-squares regression analysis (GraphPad Prism, GraphPad Software, San Diego, CA).Vmax/Km ratios were determined as a rough calculation of metabolic clearance. Data are given as mean ± S.D. Linear correlation analyses between kinetic and physicochemical parameters were examined where Hammet ς and π values were from a standard text (Kubinyi, 1995), and partition coefficient (log P, n-octanol/water) and pKa were calculated with the ACD program (Advanced Chemistry Development Inc., Toronto, ON, Canada).
Results
The separation of the glucuronide metabolites was achieved using a gradient reversed-phase HPLC method. Since this method used acetonitrile and 10 mM perchloric acid (pH 2.5) as solvent systems and also 1% perchloric acid was used in sample preparation for analysis, a stability study was conducted with the glucuronide of 1a (5 mM) over the pH range encountered in analysis. After 48 h of incubation at 37°C in 1 N HCl, 1% perchloric acid, and Tris buffer, pH 7.4, the percentage of the glucuronide remaining was determined to be 98.3 ± 3.2, 98.8 ± 2.0, and 98.2 ± 4.9%, respectively. The identity of each N-glucuronide metabolite produced by expressed enzymes was indicated by comparison of the HPLC retention times under various chromatographic conditions with the metabolite produced by incubation of the same substrate with hepatic microsomes. In the latter case, each metabolite was identified by mass spectrometry, reaction dependence on the addition of UDPGA, and susceptibility to β-glucuronidase treatment (unpublished work).
1-Substituted imidazoles 1b to 1h were screened against a panel of nine recombinant expressed human UGT enzymes. WhereN-glucuronidation occurred, the data determined by the analysis of the microsomal mixture by HPLC-UV are given in Table1. For six of the seven substrates examined, only UGT1A4 (human lymphoblast-expressed) was detected to give the N+-glucuronide metabolite. This is in contrast to the 1-phenyl compound 1a (Table 1), where in previous work (Vashishtha et al., 2000) and confirmed in the present work, both UGT1A3 and UGT1A4 were identified to catalyze N-glucuronidation. In the case of the 1-(4-nitrophenyl) compound 1h , none of the UGTs examined were detected to produce a metabolite. The observed UGT1A4-catalyzed activities for the series of 1-substituted substrates were in the range 3 to 82 pmol/min/mg of protein.
N-Glucuronidation kinetics of the series 1 compounds were determined for UGT1A4 expressed in baculovirus-infected insect cells. The N-glucuronidation activities ( 1a , 1b , 1d –1g ) observed with this preparation were greater than for the preparation involving UGT1A4 expressed in human lymphoblastoid cells, although the difference in activity was not accurately determined. The incubation conditions for the kinetic measurements were optimized. The optimum pH for theN-glucuronidation was observed either at pH 7.4 or to plateau in the pH 7.4 to 9 range, as shown for the 1-phenyl compound 1a (Fig. 2). In further work all substrates were investigated at pH 7.4. Regarding latency disrupting agents, preliminary investigation of alamethicin and five detergents at 100 μg/mg of protein concentration gave a change in catalytic activity of the N-glucuronidation of 1a that varied from a slight increase to a marked decrease (alamethicin, −14.2%; Brij-58, −21.8%; CHAPS, −92.5%; Emulgen 911, +11.2%; Lubrol PX, −3.5%; and Triton X-100, −9.5%). Subsequent study of alamethicin and Emulgen 911 over wide concentration ranges, as well as various sonication techniques, showed that in each case the affected increase in catalytic activity did not exceed 25% (Fig.3). Alamethicin at a concentration of 10 μg/mg of protein gave observed optimal activity for both substrates examined ( 1a and 1d ), and hence this latency-disrupting agent condition was used for kinetic studies. Depending upon the substrate, the rate of N-glucuronidation was linear up to 45 ( 1f ), 50 ( 1a ), and 60 min ( 1b , 1d , 1e , and 1g ). Regarding protein concentration, the rate of glucuronidation was linear up to 1.0 mg of protein for all the substrates examined.
The kinetic parameters obtained for the series
1
compounds by nonlinear regression analysis of the data plotted between the rate of formation under optimized conditions of the metabolite and substrate concentration are shown in Table 2. For
1a
,
1b
, and
1d
to
1g
there were 17.5-, 2.2-, and 8.7-fold variation in the apparentKm (range, 0.18–3.15 mM) andVmax (range, 0.16–0.35 nmol/min/mg of protein) values, andVmax/Km ratios (range, 0.11–0.95 μl/min/mg of protein), respectively. Linear correlation analyses between these three apparent kinetic parameters and either pKa, electronic properties (ςpara), or lipophilicity (πpara or log P) revealed the following correlations:
Discussion
Six of the seven 1-substituted imidazoles examined were glucuronidated. The site of glucuronidation was probably at the imidazole 3N position, as proven in the case of the previously studied 1-phenyl-substituted compound (Vashishtha et al., 2000; unpublished work). This is consistent with the general pattern observed for published reports involving the site ofN-glucuronidation of five-membered heterocyclic ring systems with more than one ring nitrogen atom. In general, where a ring nitrogen atom is substituted, as in the present study, aN+-glucuronide metabolite is formed at a ring aromatic-type tertiary amine (Midgley et al., 1981;Takeuchi et al., 1989; MacRae et al., 1990; Rush et al., 1990, 1992;McCann et al., 1997), whereas where ring substitution is only via carbon atoms, a tertiary amine glucuronide is formed at a ring secondary amine group (Stearns et al., 1991; Huskey et al., 1993,1994a,b; Colletti and Krieter, 1994; Perrier et al., 1994; Kuo et al., 1999; Kaivosaari et al., 2000; Stevens et al., 2001).
The UGT isoforms involved in the glucuronidation of the series 1 compounds were identified. Of the nine UGT isoforms investigated, only UGT1A4 was found to affect catalysis of the six newly investigated 1-substituted imidazoles 1b to 1g where metabolism was observed. It is surprising that UGT1A3 was not detected to catalyze the glucuronidation of 1b to 1g , since this UGT isoform, as well as UGT1A4, glucuronidated the 1-phenyl-substituted compound 1a (Vashishtha et al., 2000). To the best of our knowledge, there are no other published investigations of UGT1A3 catalysis at an aromatic tertiary amine, although various substrates with an aliphatic tertiary amine have been demonstrated to be glucuronidated by this UGT isoform (Green et al., 1998; Breyer-Pfaff et al., 2000). However, in virtually all these documented cases, UGT1A3 catalyzed glucuronidation at lower rates than UGT1A4. In fact, a few substrates, such as trifluoperazine, were observed to be glucuronidated by UGT1A4 but not UGT1A3. Thus, there is great potential to develop UGT1A3- and UGT1A4-specific substrates by investigation of compounds where glucuronidation occurs at either an aliphatic or aromatic tertiary amine group.
The kinetic parameters for the glucuronidation of all series 1 substrates by UGT1A4 were determined at the same incubation pH of 7.4, since the glucuronidation activity either peaked at this pH value or plateaued in the pH 7.4 to 9.0 range. A similar observation has been made regarding the incubation pH for the glucuronidation of the same compounds by human liver microsomes (Vashishtha et al., 2000). The optimization of the incubation conditions for the glucuronidation of series 1 compounds by UGT1A4 with respect to the use of membrane-disrupting agents or sonication was investigated. In general, minimal effect was observed in removing the so-called latency for glucuronidation. It was previously noted (Green and Tephly, 1996) in studies with a different UGT1A4 preparation that certain detergents inhibited glucuronidation at a tertiary amine group. Notably, the use of detergents or alamethicin enhanced glucuronidation of series 1 compounds 2- to 3-fold in human liver microsomes (unpublished work), whereas in the present work, use of the same agents or sonication enhanced glucuronidation by UGT1A4 1.25-fold at most. This far lower activating effect of certain detergents or pore-forming peptides with expressed enzymes rather than microsomes may be a general phenomenon. Alamethicin was used in the kinetic studies at the optimal concentration of 10 μg/mg of protein. It was noted that as the concentration of alamethicin increased, the removal of latency effect was eventually replaced by an inhibitory effect (Fig. 3). Therefore, like detergents, the appropriate concentration of this pore-forming peptide should be determined for each substrate in the incubation mixture employed.
The enzyme activities and kinetic parameters for glucuronidation at an aliphatic tertiary amine group have been reported for various substrates with both human liver microsomes (Le Bigot et al., 1983;Dahl-Puustinen and Bertilsson, 1987; Coughtrie and Sharp, 1991;Styczynski et al., 1992; Breyer-Pfaff et al., 1997, 2000; Mey et al., 1999) and expressed UGT isoforms (Green et al., 1995, 1998; Green and Tephly, 1996, 1998; Breyer-Pfaff et al., 2000). However, such data are lacking regarding glucuronidation at an aromatic tertiary amine and are limited to the antiepileptic drug lamotrigine (Magdalou et al., 1992;Green et al., 1995; Furlan et al., 1999). Comparison of the present data for expressed UGT1A4 can be made with reported kinetic data for the same UGT isoform involving glucuronidation at an aliphatic tertiary amine group and available kinetic data for lamotrigine with human liver microsomes (Furlan et al., 1999;Km for healthy livers, 5.5 ± 5.2 mM). The apparent Km is considered an appropriate kinetic parameter to make a comparison between substrates of an enzyme, whereas the Vmax shows wide variability between different expressed enzyme preparations of the same UGT, demonstrated in this work by the difference in catalytic activities obtained for the same substrate by the two UGT1A4 preparations investigated. The Km data obtained for the glucuronidation of series 1 compounds by expressed UGT1A4 (range, 0.2–3.2 mM) are either in the same range or within one order of magnitude higher than the data reported (Green and Tephly, 1996; Green et al., 1998; Breyer-Pfaff et al., 2000) for the glucuronidation of seven substrates at an aliphatic tertiary amine (range, 0.03–0.3 mM).
To undertake kinetics/physicochemical parameters correlation analysis, an adequate number of compounds is necessary, especially since more than one physicochemical parameter is probably important with respect to enzyme-substrate interaction. Eight compounds were included in the present study, but glucuronidation could not be detected for one of the substrates, and a key substrate for investigation of correlations involving lipophilicity, the phenylethyl compound 1c , could not be accurately quantified. Regarding the latter, since there were data available for only two compounds of a homologous series ( 1a and 1b ), the study of lipophilicity correlations was hampered. Nevertheless, despite the relatively low number of substrates with available kinetic data, there were statistically significant correlations between the following values:Vmax and log P or pKa and log 1/Km and pKa. The inverse correlation found between log P andVmax values can be contrasted with the parabolic relationship found for similar correlation analysis in a previous study involving only reaction rates (Kim, 1991). These previous analyses of various data sets for theO-glucuronidation of phenols by rat liver microsomes indicated that the reaction velocity was optimum at an approximate log P value of 2. In the present study, investigation of an optimum log P value is precluded due to the low number of substrates with a limited range of log P values. The correlations involving pKa values indicate that for the series 1 compounds, a high pKa is indicative of both a high Km and a highVmax. Notably, a relationship of an increase in reaction velocity with an increase in pKa was reported for one of the series of compounds in structure-metabolism relationship studies of theO-glucuronidation of phenols by rat liver microsomes (Kim, 1991). However, that glucuronidation, an SN2 reaction, only occurs within a range of pKavalues could be anticipated. In fact, no glucuronidation could be detected for the 4-nitro compound ( 1h ), the series 1 compound with a para-phenyl substituent with the largest electron withdrawing effect, and hence the lowest pKa value. A further indication that the availability of the substrate lone pair of electrons at the site of glucuronidation has relevance to the kinetics of the metabolic reaction was the relatively wide variability observed in the optimum pH for glucuronidation at an aliphatic or aromatic tertiary amine group. For example, the optimum incubation pH value of 7.4 presently found for glucuronidation at an aromatic tertiary amine of some substrates can be contrasted with the optimum value of pH 8.4 found for glucuronidation of the more basic aliphatic tertiary amine group using the present or another UGT1A4 preparation (Green et al., 1995; unpublished work). Finally, in view of the low number of substrates examined and the limited range of values for each parameter, especiallyVmax values, further study with more substrates of greater structural diversity is warranted to substantiate the present correlation analyses.
In conclusion, a series of eight 1-substituted imidazole compounds served as a prototype model for glucuronidation at an aromatic tertiary amine group of a polyaza five-membered heterocyclic ring system. WhereN-glucuronidation occurred, UGT1A4 catalyzed the metabolism. Small changes in substrate structure resulted in large changes in UGT1A4 catalysis that included loss of activity and marked change in kinetic parameters, especially Km. Despite the low number of data points for correlation analyses between substrate physicochemical parameters and enzyme kinetic constants, correlations were found between Vmax and log P or pKa and betweenKm and pKa. These correlations indicate that the lipophilicity and the ease of availability of the tertiary amine lone pair of electrons of the substrate are important with respect to enzyme catalysis.
Footnotes
-
This study was supported by an AstraZeneca academic grant (to E.M.H. and D.J.M.) and a Canadian Institutes of Health Research Operating Grant MOP-36513 (to E.M.H. and G.M). A part of this work was presented in abstract form at the 10th North American International Society for the Study of Xenobiotics Meeting, October 24 to 28, 2000, Indianapolis, IN [Drug Metab Rev32:309 (2000)].
-
1Current address: Wyeth-Ayerst Research, Princeton, NJ 08543.
-
2Current address: Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285.
- Abbreviations used are::
- UGT
- UDP-glucuronosyltransferase
- UDPGA
- UDP-glucuronic acid
- CHAPS
- 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid
- HPLC
- high-pressure liquid chromatography
- Received March 27, 2001.
- Accepted June 25, 2001.
- The American Society for Pharmacology and Experimental Therapeutics